Alphamab Oncology (HKSE:09966) Gross-Profit-to-Asset % : 9.20% (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Alphamab Oncology's annualized Gross Profit for the quarter that ended in Jun. 2023 was HK$226.0 Mil. Alphamab Oncology's average Total Assets over the quarter that ended in Jun. 2023 was HK$2,455.7 Mil. Therefore, Alphamab Oncology's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 9.20%.

Alphamab Oncology Gross-Profit-to-Asset % Historical Data

The historical data trend for Alphamab Oncology's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Gross-Profit-to-Asset % Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

5.44

4.82

7.61

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial								11.06	2.93	7.14	9.20	5.40

Competitive Comparison of Alphamab Oncology's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Alphamab Oncology's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Gross-Profit-to-Asset % falls into.

Alphamab Oncology Gross-Profit-to-Asset % Calculation

Alphamab Oncology's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	136.952	/	( (3312.296	+	2364.678)	/ 2 )
	=	136.952	/	2838.487
	=	4.82 %

Alphamab Oncology's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	225.976	/	( (2364.678	+	2546.747)	/ 2 )
	=	225.976	/	2455.7125
	=	9.20 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Alphamab Oncology Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines